Compare GSK plc (GSK) vs Iris Energy Limited (IREN) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

IREN is trading at $36.28, down 5.99% in the last session, amid a bearish technical outlook with selling pressure across moving averages. The company shows strong revenue growth projections, with 2026 revenue expected to reach $757 million and net profit margin improving to 20.87%. Recent executive appointments and AI infrastructure expansion signal strategic transformation, though the stock faces execution risks and negative profitability metrics.

The investment case hinges on IREN's successful pivot to AI cloud infrastructure, supported by analyst consensus of $79.11 price target and 71% buy ratings. However, negative ROE (-9.58%) and consecutive earnings misses present significant execution risks, while technical indicators suggest near-term pressure with support at $35.